Business
Does Canada’s shrinking medical cannabis market offer lessons for other nations?
Canada’s regulated medical cannabis market has dwindled significantly from its peak, declining well before recreational marijuana legalization in October 2018 and continuing that downward trend as adult-use sales displaced purchases through regulated medical channels.
Experts say factors behind the medical market’s decline include:
- The convenience of shopping at adult-use stores.
- Challenges for doctors in authorizing medical cannabis.
- A lack of tax advantages for medical cannabis clients and producers.
- THC potency limits that apply to both recreational and medical cannabis products.
Those issues might offer lessons for other nations and jurisdictions that legalize medical marijuana first, followed by adult-use legalization.
In Canada, spending on medical cannabis products peaked about a year before recreational cannabis sales began, reaching 161 million Canadian dollars ($120 million) in the fourth quarter of 2017, according to Statistics Canada data.
The most recent data shows medical marijuana sales totaled CA$109 million in the second quarter of 2022, after hitting a low of CA$104 million in the first quarter.
“Right now, what’s happening is the patients, they just give up and they just go buy something” from an adult-use store, said Brett Zettl president and CEO of Saskatoon, Saskatchewan-based medical cannabis company Zyus Life Sciences, which is preparing to go public via a reverse takeover.
“And so, they’re self-medicating without any medical oversight whatsoever.”
Canada was the first major global economy to legalize recreational cannabis at the federal level.
However, mature marijuana markets in the United States such as Colorado have exhibited a similar dynamic, with medical markets shrinking after recreational legalization.
Those trends raise the question of whether a similar medical market decline could occur in Germany, Europe’s biggest cannabis market, if that country follows through on its adult-use legalization plan.
Some Germans pay out-of-pocket for medical cannabis, and that subset of the market stands to be affected by adult-use legalization, said Deepak Anand, a board member of nonprofit advocacy group Medical Cannabis Canada and a consultant on marijuana regulations for several international governments.
However, Anand said roughly 40% of all German medical cannabis prescriptions are reimbursed by the public health system.
“I don’t think that the trajectory that we’ve seen in legal markets where, basically, post-(recreational) legalization we see medical sales have declined, will necessarily continue in Germany,” Anand said.
‘The hassle factor’
Canadians wishing to access medical marijuana products such as dried cannabis, edibles, oils or topicals through the government’s system require an authorization by a physician or nurse practitioner, allowing them to buy cannabis directly from licensed producers for mail delivery.
Home medical cannabis cultivation is also permitted, as is sourcing supply from a designated grower.
Only about 42,000 individuals produced medical cannabis for themselves or others as of the end of 2021, according to Health Canada.
In comparison, there were roughly 257,000 registrations to buy cannabis from a commercial producer (individuals can register with more than one producer).
Several factors might explain why the Canadian medical marijuana market has declined from its 2017 peak, according to Zettl, a longtime presence in Canada’s regulated MMJ industry.
Ahead of recreational legalization in October 2018, Zettl said, Canada’s medical cannabis patient population included both “true medical users” and some recreational users.
“They would try to get it legitimately and then still use it recreationally,” Zettl explained.
Now, he said, using the formal medical marijuana stream has become inconvenient compared to buying cannabis at an adult-use store.
Zettl also believes doctors might not want to spend time filling out medical cannabis authorization paperwork and that physicians who authorize cannabis for too many patients could face unwanted audits by medical-certification bodies.
“People just don’t want the hassle factor,” Zettl said. “The doctors don’t want the hassle factor.”
Other medical marijuana challenges
Cannabis consultant Anand cited some other factors contributing to the Canadian MMJ market’s decline.
“Pre-(recreational) legalization, there were a number of challenges with respect to form factors,” Anand said.
New forms of cannabis, including edibles, hit the market after adult-use legalization, but medical marijuana products are subject to the same regulations as recreational cannabis – including THC limits on products such as edibles.
Holding “medical and recreational cannabis to the same standards, with respect to putting on limits for high THC, for example, that is a mistake,” Anand said.
He believes Canada has been so focused on recreational legalization that “not only have patients been ignored, but also regulatory policy has been ignored to a large extent.”
“And what we saw, and what we’re seeing is, patients are going to the legacy or the illicit market to be able to access their products,” he continued.
The affordability of cannabis was another historical challenge for the medical market, Anand added.
“Obviously, we’ve seen that improve post-(recreational) legalization.”
Canada offers little in the way of preferential tax treatment for registered medical cannabis clients, although it does permit registered patients to claim medical marijuana expenses on their annual tax returns.
Patients pay retail taxes on medical marijuana purchases, as they would at a recreational store, and producers pay the same excise taxes as they do for adult-use cannabis.
That “just doesn’t make sense,” Anand said.
“We don’t charge tax on any other pharmaceutical products in Canada.”
Finding growth again
Anand called for policy changes to get Canada’s medical marijuana market growing again.
“Allowing pharmacies to be able to dispense medical cannabis is a no-brainer – that should be immediate,” he said.
“Eliminating tax should be another immediate step that we want to take, and eliminating potency limits.”
Canada’s federal Cannabis Act is currently under review, and the Canadian cannabis industry is hoping for reforms.
The government lists the “impact of legalization and regulation of cannabis on access to cannabis for medical purposes” as one of its “key themes” for the review.
Zyus’ Zettl said the government is using “this recreational-style act to oversee and regulate the medical side – and it’s basically coming at a massive disservice for the medical usage, both on the doctor side and the patient side.”
In terms of finding growth in Canada’s medical marijuana market, Zettl said Zyus is developing three cannabis drug-product candidates and hopes to eventually receive formal Drug Identification Numbers (DINs) from Health Canada.
He said such products could “become the holy grail,” because they could be included in insurance company prescription-drug formularies and doctors could prescribe them without worrying about scrutiny from their regulators.
Zettl acknowledged that achieving DINs for herbal cannabis products is a long-term goal.
“So medical cannabis in the meantime, though, has to find ways to appeal to the individuals who are really, truly using it medically and provide some kind of reason for them not to just give up and start just buying (from recreational stores).”
Business
Alleged Crores Pharma Scam Mastermind Arrested from Surat
After evading law enforcement for nearly 13 years, an accused linked to a large-scale pharmaceutical fraud case has been arrested by Delhi Police from Surat, Gujarat. The suspect is alleged to have orchestrated a series of financial scams involving fake identities, forged documents, and dishonoured cheques used to procure high-value pharmaceutical raw materials.
Authorities say the accused, identified as Himmat Singh Lodha, is believed to have defrauded multiple pharmaceutical companies in Delhi of goods worth approximately ₹98 lakh before disappearing and remaining underground for years.
Fake Business Deals and Dishonoured Cheques Used in Fraud
Investigators claim the accused posed as a legitimate pharmaceutical trader and placed bulk orders for expensive drug ingredients, offering post-dated cheques as payment security.
In one documented case from 2013, he allegedly obtained around 550 kilograms of Gliclazide, a diabetes-related pharmaceutical ingredient, valued at over ₹26 lakh. When suppliers attempted to encash the cheques, they were reportedly returned with the remark “account closed.”
Following the transaction, the accused allegedly vacated his office and rented residence and disappeared without settling payments. He was later declared a proclaimed offender in 2016 after repeatedly failing to appear before court proceedings. Authorities had also issued a reward for information leading to his arrest.
Multiple Identities and Repeated Fraud Pattern
Police investigations further link the accused to another cheating case dating back to 2012, where he allegedly used a fake identity, “Kailash Jain,” to obtain a large consignment of Ambroxol HCL, a pharmaceutical compound used in cough medications. The value of that consignment was estimated at around ₹72 lakh.
Officials believe the accused followed a consistent modus operandi—posing as a credible businessman, securing high-value goods on deferred payment terms, and then disappearing after delivery while shutting down business operations.
Investigators suspect that forged business records, fake company credentials, and fabricated financial histories were used to build trust with suppliers and gain access to expensive raw materials.
Multi-State Surveillance Leads to Arrest in Surat
A special Crime Branch team tracked the accused through coordinated surveillance efforts across multiple cities, including Mumbai, Ahmedabad, and Surat. After nearly a month of technical monitoring and intelligence gathering, officials located and arrested him from a residential area in Surat.
Authorities also revealed that the accused had been involved in property-related activities while staying under the radar to avoid detection.
Growing Threat of Corporate Identity Fraud
The case highlights a rising trend of organised financial fraud targeting industries that rely heavily on trust-based transactions and deferred payments. Experts note that criminals increasingly exploit gaps in corporate verification systems by using fake GST registrations, temporary offices, and forged documentation to appear legitimate.
Cybercrime and financial fraud specialists warn that such schemes are becoming more complex with the widespread availability of digital business tools, making it easier to create convincing but fraudulent corporate identities.
Experts Urge Stronger Due Diligence in High-Value Transactions
Experts, including former IPS officer and cybercrime specialist Prof. Triveni Singh, emphasize the need for stricter verification procedures in commercial dealings. He noted that relying solely on paperwork or digital business profiles can expose companies to significant financial risk.
Authorities and industry experts recommend physical verification of business operations, bank account validation, and detailed background checks before engaging in high-value or deferred-payment transactions—particularly in sectors like pharmaceuticals, where single consignments can involve transactions worth crores.
Business
EU Pressure Builds on Google as Regulators Face Calls for Massive Fine Over Search Practices
A growing coalition of European industry groups is intensifying pressure on regulators to take decisive action against Google over allegations of unfair search practices that could reshape competition rules across the region’s digital economy.
Investigation Under Digital Markets Act Gains Momentum
The case is being examined by the European Commission under the European Union’s landmark Digital Markets Act (DMA), introduced to curb the dominance of major technology platforms and ensure fair competition.
Launched in March 2024, the investigation focuses on whether Google has been prioritising its own services in search results, potentially disadvantaging rival businesses that rely on online visibility to reach customers.
Industry Groups Demand Swift Action
Several prominent European organizations have jointly urged regulators to conclude the probe without further delay. They argue that prolonged investigations allow alleged anti-competitive practices to continue, putting European companies—especially startups—at a disadvantage.
Signatories include the European Publishers Council, the European Magazine Media Association, the European Tech Alliance, and EU Travel Tech.
In a joint statement, these groups warned that delays in enforcement are affecting innovation, profitability, and growth prospects for regional businesses competing in digital markets.
Google Denies Allegations
Google has rejected claims of bias, stating that its search algorithms are designed to deliver the most relevant and useful results to users. The company has also proposed adjustments to address regulatory concerns.
However, critics argue that these changes are insufficient and fail to address the core issue of market dominance.
Potential Billion-Euro Penalties
If found in violation of the DMA, Google could face significant financial penalties. Under EU rules, fines can reach a substantial percentage of a company’s global turnover, potentially amounting to billions of euros.
Regulators may also impose corrective measures requiring changes to business practices, which could have long-term implications for how digital platforms operate in Europe.
Wider Implications for Big Tech
The case highlights ongoing tensions between European regulators and major U.S. technology firms. In recent years, the EU has taken a more aggressive stance in enforcing competition laws, aiming to create a level playing field for local businesses.
A final ruling against Google could set a major precedent, influencing future enforcement actions and shaping the regulatory landscape for global tech companies operating within Europe.
As scrutiny intensifies, the outcome of the investigation is expected to play a critical role in defining the future of digital competition across the European Union.
AI & Technology
Amazon Faces Potential Criminal Trial in Italy Over €1.2 Billion Tax Evasion Allegations
Milan: U.S. tech giant Amazon is facing the prospect of a major legal showdown in Italy, after prosecutors in Milan formally requested a court to move forward with criminal proceedings over alleged tax evasion totaling approximately ₹12,500 crore (€1.2 billion).
The case targets Amazon’s European division along with four senior executives, marking one of the most significant tax-related investigations involving a global e-commerce platform in Europe.
Trial Push Despite Multi-Million Euro Settlement
The move comes even after Amazon reached a financial settlement with Italian tax authorities in December, agreeing to pay around ₹5,500 crore (€527 million), including interest, to resolve part of the dispute.
Typically, such settlements lead to the closure of criminal investigations. However, Milan prosecutors have opted to proceed, signaling a tougher stance on alleged corporate tax violations.
A preliminary hearing is expected in the coming months, where a judge will decide whether to formally indict the company and its executives or dismiss the case.
Allegations of VAT Evasion Through Marketplace Sellers
At the center of the investigation are claims that Amazon’s platform enabled non-European Union sellers to avoid paying value-added tax (VAT) on goods sold to Italian consumers between 2019 and 2021.
Prosecutors allege that the company’s marketplace structure allowed thousands of foreign vendors—many reportedly based in China—to operate without fully disclosing their identities or tax obligations. This, authorities argue, led to substantial VAT losses for the Italian government.
Under Italian law, online platforms facilitating sales can be held partially liable if third-party sellers fail to comply with tax requirements, a key point in the prosecution’s case.
Italian Government Named as Affected Party
In their filing, prosecutors identified Italy’s Economy Ministry as the injured party, citing significant financial damage resulting from the alleged tax evasion.
Legal experts say the outcome of the case could have wide-ranging implications across the European Union, where VAT systems are harmonized and similar compliance rules apply to digital marketplaces.
Multiple Investigations Add to Pressure
The VAT probe is just one of several legal challenges facing Amazon in Italy. The European Public Prosecutor’s Office is reportedly examining additional tax-related issues covering more recent years.
Meanwhile, Milan authorities are pursuing separate investigations into alleged customs fraud linked to imports from China and whether Amazon maintained an undeclared “permanent establishment” in Italy—potentially exposing it to higher tax liabilities.
In a separate regulatory action, Italy’s data protection authority recently ordered an Amazon unit to stop using personal data from over 1,800 employees at a warehouse near Rome.
Amazon Denies Allegations
Amazon has consistently denied wrongdoing and indicated it will strongly contest the allegations in court if the case proceeds. The company has also warned that prolonged legal uncertainty could impact investor confidence and Italy’s appeal as a destination for international business.
Broader Impact on Europe’s Digital Economy
If the case moves to trial, it could become a landmark moment for the regulation of global e-commerce platforms in Europe. Governments across the region are increasingly scrutinizing how digital marketplaces handle tax compliance, especially in cross-border transactions.
With online retail continuing to expand, regulators are under mounting pressure to ensure that multinational platforms and third-party sellers adhere to the same tax rules as traditional businesses.
-
Business3 years agoPot Odor Does Not Justify Probable Cause for Vehicle Searches, Minnesota Court Affirms
-
Business3 years agoNew Mexico cannabis operator fined, loses license for alleged BioTrack fraud
-
Business3 years agoAlabama to make another attempt Dec. 1 to award medical cannabis licenses
-
Business3 years agoWashington State Pays Out $9.4 Million in Refunds Relating to Drug Convictions
-
Business3 years agoMarijuana companies suing US attorney general in federal prohibition challenge
-
Business3 years agoLegal Marijuana Handed A Nothing Burger From NY State
-
Business3 years agoCan Cannabis Help Seasonal Depression
-
Blogs3 years agoCannabis Art Is Flourishing On Etsy
